%0 Journal Article %A Sonia Pérez-Rodríguez %A Meiby de la Caridad Rodríguez-González %A Rolando Ochoa-Azze %A Yanet Climent-Ruiz %A Carlos Alberto González-Delgado %A Beatriz Paredes-Moreno %A Carmen Valenzuela-Silva %A Laura Rodríguez-Noda %A Rocmira Perez-Nicado %A Raúl González-Mugica %A Marisel Martínez-Pérez %A Belinda Sánchez-Ramírez %A Tays Hernández-García %A Alina Díaz-Machado %A Maura Tamayo-Rodríguez %A Alis Martín-Trujillo %A Jorman Rubino-Moreno %A Anamary Suárez-Batista %A Marta Dubed-Echevarría %A María Teresa Pérez-Guevara %A Mayté Amoroto-Roig %A Yanet Chappi-Estévez %A Gretchen Bergado-Báez %A Franciscary Pi-Estopiñán %A Guang-Wu Chen %A Yuri Valdés-Balbín %A Dagmar García-Rivera %A Vicente Vérez-Bencomo %T A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: safety, reactogenicity and immunogenicity %D 2021 %R 10.1101/2021.10.04.21264522 %J medRxiv %P 2021.10.04.21264522 %X Background The Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein is the target for many COVID-19 vaccines. Here we report results for phase 1 clinical trial of two COVID-19 vaccine candidates based on recombinant dimeric RBD (d-RBD).Methods We performed a randomized, double-blind, phase I clinical trial in the National Centre of Toxicology in Havana. Sixty Cuban volunteers aged 19-59 years were randomized into three groups (20 subjects each): 1) FINLAY-FR-1 (50 mcg d-RBD plus outer membrane vesicles from N. meningitidis); 2) FINLAY-FR-1A-50 mcg d-RBD (three doses); 3) FINLAY-FR-1A-25 mcg d-RDB (three doses). The FINLAY-FR-1 group was randomly divided to receive a third dose of the same vaccine candidate (homologous schedule) or of FINLAY-FR-1A-50 (heterologous schedule). The primary outcomes were safety and reactogenicity. The secondary outcome was vaccine immunogenicity. Humoral response at baseline and following each vaccination was evaluated using live-virus neutralization test, anti-RBD IgG ELISA and in-vitro neutralization test of RBD:hACE2 interaction.Results Most adverse events were of mild intensity (63.5%), solicited (58.8%), and local (61.8%); 69.4% with causal association with vaccination. Serious adverse events were not found. The FINLAY-FR-1 group reported more adverse events than the other two groups. After the third dose, anti-RBD seroconversion was 100%, 94.4% and 90% for the FINLAY-FR-1, FINLAY-FR-1A-50 and FINLAY-FR-1A-25 respectively. The in-vitro inhibition of RBD:hACE2 interaction increased after the second dose in all formulations. The geometric mean neutralizing titres after the third dose rose significantly in the group vaccinated with FINLAY-FR-1 with respect to the other formulations and the COVID-19 Convalescent Serum Panel. No differences were found between FINLAY-FR-1 homologous or heterologous schedules.Conclusions Vaccine candidates were safe and immunogenic, and induced live-virus neutralizing antibodies against SARS-CoV-2. The highest values were obtained when outer membrane vesicles were used as adjuvant.Trial registry https://rpcec.sld.cu/en/trials/RPCEC00000338-EnCompeting Interest StatementSome authors are researchers of Finlay Vaccine Institute, and the Centre of Molecular Immunology, the institutions that manufacture the vaccines.Clinical Trialhttps://rpcec.sld.cu/en/trials/RPCEC00000338-EnClinical Protocols https://rpcec.sld.cu/en/trials/RPCEC00000338-En) Funding StatementPartial funding for this study was received from Fondo de Ciencia e Innovacion (FONCI) of Cuba Ministry of Science, Technology and the Environment (Project-2020-20).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Cuban Ministry of Public Health (MINSAP), the Independent Ethics Committee (IEC) for Studies on Human Subjects, at CENATOX and the Cuban National Regulatory Agency (Centre for State Control of Medicines and Medical Devices, CECMED), approved the trial and the procedures (CECMED, Authorization date: 13/10/2020, Reference number: 05.013.20BA. It was conducted according to the Declaration of Helsinki and Good Clinical Practice. An Independent Data Monitoring Committee (IDMC) analysed safety, reactogenicity, and immunogenicity data. During recruitment, investigators provided potential participants with extensive oral and written information. The decision to participate in the study was completely voluntary. Written informed consent was obtained from all volunteers. During the study, the IEC and IDMC assessed the trial risk-benefit ratio and assured the rights, health and privacy of volunteers, including information confidentiality. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesInformation is available at the Cuban Public Registry of Clinical Trials, included in WHO International Clinical Trials Registry Platform (Soberana 01A, RPCEC https://rpcec.sld.cu/en/trials/RPCEC00000338-En). Other supporting clinical data and documents, including immunological individual data, will be available after publication of this article through direct request to: ochoa{at}finlay.edu.cu or: vicente.verez{at}finlay.edu.cu. %U https://www.medrxiv.org/content/medrxiv/early/2021/10/05/2021.10.04.21264522.full.pdf